Sign in →

Test Code NGPLSB OncoPlus, Universal Cancer Mutation Analysis Panel (NGS), Peripheral Blood

Important Note

Starting on 01/09/2017, the University of Chicago Molecular Pathology Laboratory launched an updated version of the OncoPlus universal cancer mutation analysis panel. This is a Next Generation Sequencing assay designed to interrogate over 1,200 solid tumor and hematological malignancy related genes via analysis of Peripheral Blood, Bone Marrow, Formalin-Fixed Paraffin-Embedded and Cytology Smear specimens. 28 additional genes were added to the previously 119 clinically reported genes.

In addition, this updated panel version allows:

  • The detection and reporting of copy number variations (CNVs) for 136 genes.
  • The detection and reporting of lung cancer-related gene fusions in ALK, RET, and ROS1.

Test includes

  • Detection of mutations, insertions and deletions for 147 clinically reported genes.
  • Detection and reporting of copy number variations (CNVs) for 136 genes.
  • Detection and reporting of lung cancer-related gene fusions in ALK, RET, and ROS1.

Specimen Type

Peripheral Blood

Container

Lavender Top (EDTA)

Preferred Volume

5 mL

Mimimum Volume

200 uL

Offsite Collection Instructions

Peripheral Blood samples collected in EDTA (lavender top) transported at room temperature to UCM Lab Services Center.

UCMC Collection Instructions

Peripheral Blood samples collected in EDTA (lavender top), stored at room temperature or refrigerator. Samples should be sent no later than 48 hours from the time of collection to UCM Lab Services Center at ambient temperature.

Availability

Monday – Friday, 8:00am – 5:00pm

Turnaround Time

14-20 business days

STAT Availability

Not Available

Test Usage

The OncoPlus panel is a universal cancer mutation, next generation sequencing (NGS) assay that has the capability to cover more than 1,200 cancer-related genes for personalized assessments of both solid tumors and hematological malignancies. 

 

  • 147 genes shown below are clinically reportable for mutations, insertions and deletions:

 

ABL1, AKT1, ALK, APC, ARID1A, ARID2, ASXL1, ATM, ATR, ATRX, AXL, B2M, BAP1, BCOR, BCORL1, BIRC3, BLM, BRAF, BRCA1, BRCA2, BTK, CALR, CBL, CBLB, CCND1, CCND2, CCND3, CDH1, CDKN2A, CEBPA, CHEK1, CHEK2, CSF1R, CSF3R, CTCF, CTNNA1, CTNNB1, CUX1, CXCR4, DAXX, DDR2, DDX3X, DDX41, DICER1, DNMT3A, EGFR, EP300, EPHA3, EPHA5, ERBB2, ERBB3, ERBB4, ERCC3, ESR1, ETV6, EZH2, FANCA, FAT3, FBXW7, FGFR1, FGFR2, FGFR3, FH, FLT3, FOXL2, GATA1, GATA2, GNA11, GNAQ, GNAS, GRIN2A, H3F3A, HIST1H3B, HIST1H3C, HNF1A, HRAS, IDH1, IDH2, IKZF1, ITPKB, JAK2, KDM6A, KDR, KIT, KMT2A, KRAS, MAP2K1, MAPK1, MET, MLH1, MLH3, MPL, MRE11A, MSH2, MSH6, MTOR, MYD88, NBN, NF1, NF2, NFE2L2, NOTCH1, NOTCH2, NPM1, NRAS, PALB2, PBRM1, PDGFRA, PDGFRB, PHF6, PIK3CA, PIK3CB, PIK3R1, PLCG2, POLE, POT1, PPP2R1A, PTCH1, PTEN, PTPN11, RAD21, RAD51, RB1, RET, RUNX1, SDHB, SDHC, SDHD, SETBP1, SF3B1, SMAD4, SMARCB1, SMC1A, SMC3, SMO, SRSF2, STAG2, STK11, TERT, TET2, TP53, TSC1, TSC2, U2AF1, VHL, WT1, and ZRSR2.

  • Genes reported for copy number gains and losses (136):

ABL1, AKT1, ALK, APC, ARID1A, ARID2, ASXL1, ATM, ATR, AXL, B2M, BAP1, BIRC3, BLM, BRAF, BRCA1, BRCA2, CALR, CBL, CBLB, CCND1, CCND2, CCND3, CDH1, CDKN2A, CEBPA, CHEK1, CHEK2, CSF1R, CSF3R, CTCF, CTNNA1, CTNNB1, CUX1, CXCR4, DAXX, DDR2, DDX41, DICER1, DNMT3A, EGFR, EP300, EPHA3, EPHA5, ERBB2, ERBB3, ERBB4, ERCC3, ESR1, ETV6, EZH2, FANCA, FAT3, FBXW7, FGFR1, FGFR2, FGFR3, FH, FLT3, FOXL2, GATA2, GNA11, GNAQ, GNAS, GRIN2A, H3F3A, HIST1H3B, HIST1H3C, HNF1A, HRAS, IDH1, IDH2, IKZF1, ITPKB, JAK2, KDR, KIT, KMT2A, KRAS, MAP2K1, MAPK1, MET, MLH1, MLH3, MPL, MRE11A, MSH2, MSH6, MTOR, MYD88, NBN, NF1, NF2, NFE2L2, NOTCH1, NOTCH2, NPM1, NRAS, PALB2, PBRM1, PDGFRA, PDGFRB, PIK3CA, PIK3CB, PIK3R1, PLCG2, POLE, POT1, PPP2R1A, PTCH1, PTEN, PTPN11, RAD21, RAD51, RB1, RET, RUNX1, SDHB, SDHC, SDHD, SETBP1, SF3B1, SMAD4, SMARCB1, SMC3, SMO, SRSF2, STK11, TERT, TET2, TP53, TSC1, TSC2, U2AF1, VHL, and WT1.

 

  • Genes reported for fusions/translocations:

ALK, RET, and ROS1.

Test Methodology

The test procedure involves DNA extraction and quantity/quality assessment, fragmentation and library preparation, followed by pooled capture targeting the desired genomic loci. Next generation sequencing (NGS) is performed on the HiSeq 2500 system (Illumina) and downstream analysis for quality control and detection of mutations is performed via custom-design bioinformatics pipelines on a HIPAA-compliant high performance computing system within the Center for Research Informatics (CRI).  147 genes will be reported for mutations and indels, 136 genes will be reported for copy number changes, and 3 genes will be reported for fusion events. 

Critical Results - Reference range

None

Reporting - Test limitations

  • An interpretive report will be provided including mutations (and now copy numbers and fusions) listed according to interpreted pathogenicity, along with interpretative summaries. 
  • This test is intended for the detection of single-nucleotide mutations and insertions/deletions up to 60 bp in size. 
  • Internal tandem duplications of the FLT3 gene are detected at larger sizes (largest size tested = 102 bp). 
  • Copy number changes will be reported at levels greater than 2X or less than 0.6X.
  • The assay is intended for performance on specimens with >20% tumor cells and adequate overall tissue. Mutational assay sensitivity is 10% mutant allelic fraction (MAF). 
  • False-negative results of all types may occur when there is a lower than adequate tumor cell burden. 

Additional Information

  • Appropriate specimens should contain >20% tumor cells and enough total cells to produce adequate DNA yield (typically >50,000 total cells).
  • Specimens with less than 20% tumor cells may be tested at the discretion of the attending molecular pathologist.

 

CPT Code

81455

Synonyms

CNV

copy number

cancer

mutation

panel

NGS

NextGen

Sequencing

Gene